Microba Life Sciences has wrapped up a $5.41 million capital raise combining a $5 million institutional Placement and a $407,500 Share Purchase Plan, strengthening its balance sheet to accelerate growth in Australia and the UK.
- Capital raise totals $5.41 million before costs
- SPP issued 8.15 million shares at $0.05 with free attaching options
- Shareholder approval obtained for second Placement tranche and SPP securities
- Funds earmarked for diagnostics growth and new product delivery
- New options exercisable at $0.0625, expiring in three years
Capital Raising Completion and Structure
Microba Life Sciences (ASX:MAP) has completed its latest capital raising, combining a $5 million institutional Placement announced in June with a Share Purchase Plan (SPP) that raised an additional $407,500. Together, these efforts have brought approximately $5.41 million before costs into the company’s coffers. The SPP offered eligible shareholders in Australia and New Zealand the chance to invest at the same price as institutional investors, $0.05 per new share, without brokerage or fees, resulting in the issue of 8.15 million new shares.
Every valid application under the SPP was satisfied in full with no scale back, underscoring solid shareholder demand. Alongside the new shares, Microba is issuing one free attaching option per share issued under the SPP, exercisable at $0.0625 and expiring three years from the issue date. This option structure mirrors that of the institutional Placement, where one option is attached to each placement share across both tranches.
Shareholder Approval and Security Issuance Timeline
Shareholder approval was secured at Microba’s general meeting on 24 July 2026 for the issuance of securities under the SPP and the second tranche of the Placement. Following this, the company plans to issue 8.66 million new shares under the second tranche of the Placement, alongside 100 million new options attached to Placement shares, and the 8.15 million shares and options under the SPP on 29 July 2026. Trading of the SPP shares is expected to commence the following day, subject to ASX and regulatory conditions.
Strategic Use of Funds to Drive Growth
Chief Executive Officer Luke Reid emphasised the importance of this capital injection in supporting Microba’s ongoing expansion. The funds will bolster the company’s core diagnostics business across Australia and the UK, facilitating broader clinical adoption of its microbiome testing services. Additionally, the capital will support the delivery of a new testing product, aligning with Microba’s strategy to innovate and diversify its offerings in the fast-evolving microbiome health sector.
Microba has been building momentum with robust revenue growth and product development, including a new GI Navigator test scheduled for launch later this year. This capital raise complements those efforts by providing financial flexibility to scale operations and invest in product rollout.
Bottom Line?
Microba’s successful capital raise offers a financial runway to expand its microbiome diagnostics footprint and launch new products, but investors should watch how effectively the company converts this capital into sustained revenue growth.
Questions in the middle?
- How will Microba’s new testing product impact revenue and market share in the coming quarters?
- What are the key milestones for clinical adoption in the UK and Australia that investors should track?
- How might the exercise of new options influence Microba’s capital structure and share liquidity?